Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Quick facts
Marketed products
- Cephalozin · Other
- Endotoxin · Other
- ferric(III)carboxymaltose · Hematology
Ferric carboxymaltose is an iron replacement therapy that delivers ferric iron complexed with carboxymaltose to replenish depleted iron stores and treat iron deficiency anemia. - Fixed low dose tinzaparin · Cardiovascular / Thromboembolism
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. - Fluticasone proprionate 0.05% cream · Dermatology
Fluticasone propionate is a potent topical corticosteroid that suppresses local inflammatory and immune responses in the skin. - Intermediate dose dalteparin · Cardiovascular
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. - Intermediate dose enoxaparin · Cardiovascular
Intermediate dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. - Intermediate dose nadroparin · Cardiovascular
Nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. - Intermediate dose tinzaparin · Cardiovascular / Hematology
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. - Low dose dalteparin · Cardiovascular
Low-dose dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. - Low dose nadroparin · Cardiovascular
Low-dose nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. - Placebo (for flucloxacillin)
A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes. - PRECISION dosing Infliximab · Immunology
Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses. - Rapidly Cycled HAART · Infectious Disease / Virology
Rapidly Cycled HAART is a highly active antiretroviral therapy regimen that uses rapid rotation or cycling of different antiretroviral drug classes to suppress HIV replication and potentially reduce resistance development. - Reduced noradrenaline use · Critical Care / Intensive Care Medicine
Reduced noradrenaline use refers to a clinical practice or protocol aimed at minimizing the administration of noradrenaline (norepinephrine) in patient care.
Phase 3 pipeline
- anti-tumour necrosis factor α antibodies · Immunology
Anti-TNF-α antibodies bind to and neutralize tumor necrosis factor alpha, a key pro-inflammatory cytokine, thereby reducing inflammation and immune-mediated tissue damage. - Infliximab subcutaneous · Immunology
Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. - Mercaptopurine (Purinethol) · Oncology; Immunology
Mercaptopurine is a purine analog that inhibits de novo purine synthesis and is converted to active metabolites that interfere with DNA and RNA synthesis, leading to cell death. - Targeted Systemic Therapy · Oncology
Targeted Systemic Therapy is a cancer treatment designed to selectively target and destroy malignant cells while minimizing damage to healthy tissue.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: